Brief: HLS Therapeutics - Effective August 1, Entered Product Listing Agreement With Saskatchewan Drug Plan, For Listing & Public Reimbursement Of Vascepa
02/08/2022 12:11
Aug 2 (Reuters) - HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS - EFFECTIVE AUGUST 1, ENTERED PRODUCT
LISTING
AGREEMENT WITH SASKATCHEWAN DRUG PLAN, FOR LISTING & PUBLIC
REIMBURSEMENT OF VASCEPA
* HLS THERAPEUTICS - UNDER TERMS OF PLA, VASCEPA WILL BE
REIMBURSED FOR SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS IN
STATIN-TREATED PATIENTS
Source text for Eikon: ID:nCNWjxRSPa
Further company coverage: HLS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsCanada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group
Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance
Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease